Targeted Therapies in Chronic Myeloid Leukemia

Elias Jabbour, Jorge Cortes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with the interaction between the BCR-ABL protein and adenosine triphosphate (ATP), blocking cellular proliferation of the malignant clone. Three TKIs are commercially available for the front-line treatment of CML: imatinib, dasatinib, and nilotinib. With the updates of the DASISION and ENESTnd trials, the question often arises as to the optimal choice for front-line management of CP-CML. Based on attainment of faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), and complete molecular response (CMR), and a trend for lower progression rates to accelerated phase (AP) or breakpoint cluster, it is reasonable to use a second generation TKI for front-line management.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley-Blackwell
Pages111-120
Number of pages10
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Busulfan
Hydroxyurea
Interferon-alpha
Cytogenetics
Therapeutics
Clone Cells
Adenosine Triphosphate
Cell Proliferation
Proteins

Keywords

  • Chronic myeloid leukemia
  • CML frontline treatment
  • Complete cytogenetic response
  • Complete molecular response
  • Dasatinib
  • Imatinib
  • Major molecular response
  • Nilotinib
  • Small-molecule tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jabbour, E., & Cortes, J. (2015). Targeted Therapies in Chronic Myeloid Leukemia. In Targeted Therapy in Translational Cancer Research (pp. 111-120). Wiley-Blackwell. https://doi.org/10.1002/9781118468678.ch11

Targeted Therapies in Chronic Myeloid Leukemia. / Jabbour, Elias; Cortes, Jorge.

Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 2015. p. 111-120.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jabbour, E & Cortes, J 2015, Targeted Therapies in Chronic Myeloid Leukemia. in Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, pp. 111-120. https://doi.org/10.1002/9781118468678.ch11
Jabbour E, Cortes J. Targeted Therapies in Chronic Myeloid Leukemia. In Targeted Therapy in Translational Cancer Research. Wiley-Blackwell. 2015. p. 111-120 https://doi.org/10.1002/9781118468678.ch11
Jabbour, Elias ; Cortes, Jorge. / Targeted Therapies in Chronic Myeloid Leukemia. Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 2015. pp. 111-120
@inbook{5a6592ed00174a6cbea32d26825db2e3,
title = "Targeted Therapies in Chronic Myeloid Leukemia",
abstract = "Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with the interaction between the BCR-ABL protein and adenosine triphosphate (ATP), blocking cellular proliferation of the malignant clone. Three TKIs are commercially available for the front-line treatment of CML: imatinib, dasatinib, and nilotinib. With the updates of the DASISION and ENESTnd trials, the question often arises as to the optimal choice for front-line management of CP-CML. Based on attainment of faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), and complete molecular response (CMR), and a trend for lower progression rates to accelerated phase (AP) or breakpoint cluster, it is reasonable to use a second generation TKI for front-line management.",
keywords = "Chronic myeloid leukemia, CML frontline treatment, Complete cytogenetic response, Complete molecular response, Dasatinib, Imatinib, Major molecular response, Nilotinib, Small-molecule tyrosine kinase inhibitors",
author = "Elias Jabbour and Jorge Cortes",
year = "2015",
month = "10",
day = "30",
doi = "10.1002/9781118468678.ch11",
language = "English (US)",
isbn = "9781118468579",
pages = "111--120",
booktitle = "Targeted Therapy in Translational Cancer Research",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Targeted Therapies in Chronic Myeloid Leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with the interaction between the BCR-ABL protein and adenosine triphosphate (ATP), blocking cellular proliferation of the malignant clone. Three TKIs are commercially available for the front-line treatment of CML: imatinib, dasatinib, and nilotinib. With the updates of the DASISION and ENESTnd trials, the question often arises as to the optimal choice for front-line management of CP-CML. Based on attainment of faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), and complete molecular response (CMR), and a trend for lower progression rates to accelerated phase (AP) or breakpoint cluster, it is reasonable to use a second generation TKI for front-line management.

AB - Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with the interaction between the BCR-ABL protein and adenosine triphosphate (ATP), blocking cellular proliferation of the malignant clone. Three TKIs are commercially available for the front-line treatment of CML: imatinib, dasatinib, and nilotinib. With the updates of the DASISION and ENESTnd trials, the question often arises as to the optimal choice for front-line management of CP-CML. Based on attainment of faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), and complete molecular response (CMR), and a trend for lower progression rates to accelerated phase (AP) or breakpoint cluster, it is reasonable to use a second generation TKI for front-line management.

KW - Chronic myeloid leukemia

KW - CML frontline treatment

KW - Complete cytogenetic response

KW - Complete molecular response

KW - Dasatinib

KW - Imatinib

KW - Major molecular response

KW - Nilotinib

KW - Small-molecule tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85015851273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015851273&partnerID=8YFLogxK

U2 - 10.1002/9781118468678.ch11

DO - 10.1002/9781118468678.ch11

M3 - Chapter

AN - SCOPUS:85015851273

SN - 9781118468579

SP - 111

EP - 120

BT - Targeted Therapy in Translational Cancer Research

PB - Wiley-Blackwell

ER -